Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimacimab in NAFLD
NCT03261739Phase 1Completed
- Sponsor
- Bird Rock Bio
- Start
- Aug 2017
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of nimacimab in non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Bird Rock Bio. Primary endpoint: Clinical evaluation of adverse events at Day 67. Started Aug 2017; status: completed.
02
Drugs
nimacimab
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03261739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261739.